Imagine targeting a tumour with sub‑millimetre precision, zapping it while sparing healthy tissue. That's modern radiation oncology. The radiation oncology market report by MRFR shows that external beam radiation therapy is the largest treatment type, and the market is growing at 8.02% CAGR — from $8.9 billion to $20.79 billion by 2035. Why the surge? Because cancer rates are rising, and patients want non‑invasive options.

What's driving growth? Breast cancer is the largest application, but prostate cancer is the fastest‑growing. The radiation oncology market analysis highlights that linear accelerators are the dominant technology, but particle therapy (proton, carbon) is the fastest‑growing — because it offers even better sparing of healthy tissue.

What's new? MR‑linac (MRI combined with linear accelerator) that images the tumour in real time, adjusting the beam as the patient breathes. Also, FLASH radiotherapy that delivers a ultra‑high dose in milliseconds, reducing damage to normal tissue.

The bottom line: if you're diagnosed with cancer, ask your oncologist about radiation options. It's not just for late‑stage palliation anymore — it's a curative tool for many early‑stage cancers.